SVRA
NASDAQ · Biotechnology
Savara Inc
$5.37
-0.05 (-0.92%)
Open$5.42
Previous Close$5.42
Day High$5.47
Day Low$5.31
52W High$7.01
52W Low$3.34
Volume—
Avg Volume1.22M
Market Cap1.11B
P/E Ratio—
EPS$-0.56
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,072.1% upside
Current
$5.37
$5.37
Target
$62.94
$62.94
$52.50
$62.94 avg
$80.97
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 135.25M | 127.87M | 115.53M |
| Net Income | 19.67M | 13.91M | 14.59M |
| Profit Margin | 14.5% | 10.9% | 12.6% |
| EBITDA | 27.67M | 31.26M | 23.85M |
| Free Cash Flow | 12.49M | 17.00M | 15.12M |
| Rev Growth | +10.1% | -5.7% | +15.6% |
| Debt/Equity | 0.38 | 0.46 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |